Deerfield Management’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Deerfield Management’s Portfolio CASC Stock Details CASC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-23,867	Closed	-$233K	–	144
2015 Q1	$233K	Sell	23,867 -42,550	-64%	-$417K	0.01%	122
2014 Q4	$757K	Sell	66,417 -309,022	-82%	-$3.35M	0.03%	105
2014 Q3	$4.33M	Buy	+375,439	New	+$5.74M	0.16%	96

Other funds holding CASC

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deerfield Management's CASC Position: Q2 2015 in Review

Deerfield Management sold out of Cascadian Therapeutics, Inc. (CASC) in Q2 2015, closing a stake of 23,867 shares — an estimated $233K sold.

Deerfield Management first reported a position in CASC in Q3 2014 and held it in 3 quarters. The position peaked at $4.33M in Q3 2014. 100 funds tracked by Wall St. Rank hold CASC as of Q2 2015.

Deerfield Management reported no remaining Cascadian Therapeutics, Inc. position as of Q2 2015 after selling out during the quarter.
Deerfield Management sold 23,867 Cascadian Therapeutics, Inc. shares in Q2 2015, an estimated $233K.
Deerfield Management first reported a position in Cascadian Therapeutics, Inc. in Q3 2014 and held it in 3 quarters.
Deerfield Management's Cascadian Therapeutics, Inc. position peaked at $4.33M in Q3 2014.
100 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q2 2015.

Based on Deerfield Management's 13F filing for Q2 2015, filed 14 Aug 2015.